Researchers Identify Germline Pathogenic Variants In CHEK2 That Identify Testicular Cancer Patients With Increased Risk For Other Cancers.

Cancer Network (2/13, Bennett) reports “researchers identified two germline pathogenic variants in checkpoint kinase 2 (CHEK2) that may account for a minority of men diagnosed with testicular germ cell tumors.” The findings could help inform men with aber...